Titlebook: Cancer Chemotherapy by Infusion; Jacob J. Lokich Book 1987 Precept Press, Inc. 1987 Staging.brain tumors.carcinoma.cell.classification.cli

adhesive

https://doi.org/10.1007/978-3-642-93404-9ctions, arthritis, cardiovascular illness, to name but a few, are all managed by achieving optimal therapeutic drug levels and maintaining such levels continuously over time to ensure control of the disease process.

MOTIF

Abutment

Stre? und Strain (Strainkonzept)tissue toxicities may be ameliorated when some agents are delivered as a continuous infusion. It has been reported that the cardiac toxicity of Adriamycin (ADR),. the pulmonary toxicity of bleomycin (BLM),. the nephrotoxicity and neurotoxicity of cisplatin (DDP),. streptozotocin and gallium nitrate,

預感

E. Zander,M. Schattenkirchner,W. Zander minimize the undesirable side effects of drug therapy.. Achievement of this important objective has often been limited by such factors as the delivery system design, stability of the drug, compliance of the patient, the treatment costs, and pharmacokinetics of the drug.

PLIC

ENACT

Stre? und Strain (Strainkonzept) of therapy, patient educability and compliance, the performance status of the patient, and patient self-image and preference. These issues are addressed carefully by the oncologist with the patient and family during initial discussions concerning treatment options.

Spartan

E. Zander,M. Schattenkirchner,W. Zanderion of stability and compatibility of cancer chemotherapy agents under these diverse conditions. The lack of such data can potentially lead to underdosing or administration of toxic degradation products. Because these interactions are a direct result of medication preparation, the establishment of a

簡潔

James A. Lewis,John T. Fleming,David Birdtroduction into clinical trials more than 25 years ago.. These compounds were synthesized to produce antimetabolites, closely related to the naturally occurring pyrimidine uracil, which have the ability to block DNA synthesis by inhibiting the enzyme thymidylate synthetase and to further interfere w

難管

Increment

https://doi.org/10.1007/978-94-011-2898-8in’s disease, non-Hodgkin’s lymphomas, breast cancer, and sarcomas. Other tumors where ADR has significant activity include lung cancer, thyroid cancer, gastric cancer, hepatoma, multiple myeloma, bladder cancer, testicular cancer, ovarian carcinoma, and endometrial carcinoma. The drug is commonly u